
Revenue
$40.00M
2023
Valuation
$1.20B
2023
Growth Rate (y/y)
74%
2023
Funding
$291.50M
2023
Revenue
Sacra estimates Viz.ai hit $40 million in revenue in 2023, up approximately 100% year-over-year from around $23 million in 2022. The company expects revenue to increase to roughly $65M in 2024.
Viz.ai has seen rapid adoption of its AI-powered care coordination platform, now used in over 1,000 U.S. hospitals covering nearly two-thirds of the population. Annual recurring revenue (ARR), a key metric for its subscription-based model, reached $12 million in 2020 and is projected to hit $100 million by 2024.
Valuation
Viz.ai reached a valuation of $1.2 billion as of April 2022, achieving unicorn status. The company has raised $289.25 million across 10 funding rounds from prominent investors including Tiger Global, Google Ventures (GV), and Kleiner Perkins Caufield & Byers.
Product

Viz.ai was founded in 2016 by Dr. Chris Mansi, a neurosurgeon, and David Golan, a machine learning postdoc. The two met at Stanford and bonded over the lack of data-driven decision making in medicine. Their initial focus was using AI to improve stroke care by reducing time to treatment.
Viz.ai found product-market fit with primary stroke centers, using AI to rapidly detect large vessel occlusion (LVO) strokes from CT scans and alert the entire care team within 7 minutes, down from 58 minutes prior. This enabled faster patient transfer to comprehensive stroke centers for thrombectomy, with Viz.ai increasing surgery volumes 50-60% at large hubs. Medicare created a new reimbursement pathway for Viz.ai's software, establishing it as a new therapeutic class.
The Viz.ai platform ingests CT scans, uses AI algorithms to identify LVOs and other critical conditions, and immediately alerts the relevant care team members on their mobile devices. This allows for rapid triage, improved communication and coordination, and faster treatment times. The platform has expanded beyond stroke to cover other time-sensitive conditions like aortic disease and pulmonary embolism.
Key features of the Viz.ai platform include:
- AI-powered identification of LVOs and other critical conditions
- Mobile alerts and communication for the entire care team
- Seamless integration with hospital workflows and systems
- Expansion to multiple specialties beyond neurology
- Demonstrated improvement in patient outcomes and treatment times
Viz.ai is now deployed in over 1,000 hospitals in the U.S. and Europe. By building an effective AI-powered platform that integrates smoothly into clinical workflows, Viz.ai has established itself as a leader in the application of AI to improve patient outcomes and streamline care delivery for time-critical conditions.
Business Model
Viz.ai is a subscription SaaS company that provides AI-powered disease detection and care coordination solutions to hospitals and health systems.
The company's core offering is a suite of FDA-approved algorithms that analyze medical images, such as CT scans, to identify potential issues like strokes, pulmonary embolisms, and aortic dissections. When the AI detects a concerning finding, it immediately alerts the appropriate specialists via a mobile app, enabling faster diagnosis and treatment.
Viz.ai generates revenue through a subscription model, charging hospitals an annual fee based on the number of algorithms they use and the size of the population they serve.
This pricing structure aligns with the value Viz.ai delivers, as its platform helps hospitals improve patient outcomes, reduce costs, and optimize resource utilization. By catching critical issues early and facilitating rapid care coordination, Viz.ai enables hospitals to treat more patients effectively and efficiently.
A key aspect of Viz.ai's business model is its focus on integrating seamlessly into existing clinical workflows.
The company's mobile app serves as a centralized communication platform, allowing specialists to collaborate, share images, and make treatment decisions quickly. This workflow integration not only enhances adoption but also positions Viz.ai as a valuable tool for driving operational improvements and reducing variability in care delivery.
As Viz.ai expands its suite of algorithms to cover more disease states, it creates opportunities for upselling and cross-selling to existing customers. The company currently has 12 FDA-approved algorithms for diseases including stroke, hypertrophic cardiomyopathy, and pulmonary embolism.
Viz.ai's land-and-expand strategy involves initially targeting high-impact areas like stroke care, then leveraging its proven value to secure broader adoption across the enterprise.
In addition to its hospital partnerships, Viz.ai has begun working with pharmaceutical and medical device companies.
As of January 2024, the company has strategic partnerships with 7 of the top 30 global life science companies. These collaborations aim to streamline product launches and accelerate patient access to new therapies.